Jan'05 | Jan'06 | Jan'07 | Jan'08 | Jan'09 | Jan'10 | Jan'11 | Jan'12 | Jan'13 | Jan'14 | Jan'15 | Jan'16 | Jan'17 | Jan'18 | Jan'19 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Return on Invested Capital (ROIC) | (17,402.2%) | (395.5%) | (172.3%) | (86.4%) | (60.0%) | (84.0%) | (162.3%) | (281.5%) | (1,038.4%) | (345.5%) | (311.7%) | (376.5%) | (423.0%) | (90.8%) | 88.3% | (309.0%) | (514.0%) | (613.3%) | (41.2%) | (56.5%) |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Microsoft Corp's last 12-month Return on Invested Capital (ROIC) is (2,476.8%), based on the financial report for Sep 30, 2024 (Q3 2024). The average annual Return on Invested Capital (ROIC) for Summit Therapeutics Inc. have been (1,587.7%) over the past three years, and (1,286.2%) over the past five years.
As of today, Summit Therapeutics Inc.'s Return on Invested Capital (ROIC) is (2,476.8%), which is lower than industry median of (130.0%). It indicates that Summit Therapeutics Inc.'s Return on Invested Capital (ROIC) is Bad.